You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 48 No. 4, April 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (22)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Positron Emission Tomography in Progressive Supranuclear Palsy

Mohit H. Bhatt, MD; Barry J. Snow, MBChB, FRACP; W. R. Wayne Martin, MD, FRCPC; Richard Peppard, MBBS, FRACP; Donald B. Calne, DM, FRCP, FRCPC

Arch Neurol. 1991;48(4):389-391.


Abstract

• Positron emission tomography with 6-[18F]fluoro-L-dopa (6-FD) provides in vivo information on the function of nigrostriatal dopaminergic neurons. We used 6-FD and positron emission tomography to investigate the integrity of the nigrostriatal system in seven patients with progressive supranuclear palsy. All patients had axial hypertonia, vertical gaze palsy, and parkinsonian features. Dementia, pyramidal signs, and ataxia were seen in varying proportions. We analyzed the scans with a graphic method to calculate a steady-state 6-FD uptake rate constant for the whole striatum. Results were compared with those obtained in seven age-matched controls. As a group, the patients with progressive supranuclear palsy had reduced 6-FD uptake constants. The 6-FD uptake constant correlated inversely with the duration of the disease. Normal positron emission tographic findings in one patient with the shortest duration of symptoms suggests that in early progressive supranuclear palsy, parkinsonism may relate to dysfunction distal to the dopaminergic neurons.



Author Affiliations

From the Neurodegenerative Disorders Center, Department of Medicine, University Hospital, and the TRIUMF PET Program, University of British Columbia, Vancouver, Canada.


Footnotes

Accepted for publication October 24, 1990.

Presented, in part, at the World Federation of Neurology Meeting, New Delhi, India, October 22-27, 1989, and at the First International Meeting of Movement Disorders, Washington, DC, April 25, 1990.

Reprint requests to Neurodegenerative Disorders Center, Department of Medicine, University of British Columbia, University Hospital, U.B.C. Site, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1W5 (Dr Calne).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Familial Progressive Supranuclear Palsy: Detection of Subclinical Cases Using 18F-Dopa and 18Fluorodeoxyglucose Positron Emission Tomography
Piccini et al.
Arch Neurol 2001;58:1846-1851.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.